Neuroprotective effect of rosuvastatin-loaded nanoemulsions against lipopolysaccharide-induced neuroinflammation and oxidative stress.
Neuroprotective effect of rosuvastatin-loaded nanoemulsions against lipopolysaccharide-induced neuroinflammation and oxidative stress.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Zanjan, IR · Author affiliation
Zanjan Pharmaceutical Nanotechnology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Neuroinflammation is a pathophysiological feature of several neurological disorders, including Parkinson's disease, Alzheimer's disease and traumatic brain injury, resulting from various intrinsic and environmental triggers. However, effective treatments are hindered by challenges in drug delivery to the central nervous system, primarily due to the blood-brain barrier. In this study, we investigated the potential of rosuvastatin-loaded nanoemulsions for neuroinflammation treatment. The mean diameter and zeta potential of developed RSV-NEs were 124.8 ± 1.23 nm and -40.5 ± 3.2 mV, respectively. TEM analysis revealed the spherical morphology and uniformity of nano-droplets. A cell viability study on the PC12 cell line confirmed the safety of RSV-NEs up to the concentration of 300 µg/mL. The protective efficacy of orally administrated RSV-NEs against LPS-induced neuroinflammation and oxidative stress was assessed in SD rats. According to histopathological assessments, LPS-induced damage was prevented by RSV-NEs through a neuroprotective effect linked to a reduction in GFAP+ cells. Moreover, TBARS levels in the rat brain cortex decreased by 3.9 times, and the cerebellum's SH increased by 1.7 times in the RSV-NEs-treated group compared to the LPS group. These findings suggest that utilising nanoemulsion delivery systems may offer improved efficacy for CNS disorders, addressing significant challenges in the management of neuroinflammatory diseases.